Multicenter, prospective, phase 2 study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
Scott R PlotkinJeffrey AllenGirish DhallJian L CampianD Wade ClappMichael J FisherRakesh K JainJames TonsgardNicole J UllrichCoretta ThomasLloyd J EdwardsBruce R KorfRoger J PackerMatthias A KarajannisJaishri O BlakelyPublished in: Neuro-oncology (2023)
Maintenance bevacizumab (5 mg/kg every 3 weeks) is associated with high rates of hearing and tumor stability during 18 months of follow-up. No new unexpected adverse events related to bevacizumab were identified in this population.